A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

Trial Profile

A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs PF 4447943 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Dec 2017 Results of a study exploring biomarkers that may be informative in demonstrating the pharmacologic effect of PF-04447943 presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Oct 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top